Send us a textUnlock the future of feline health with our special guest, Dr. Ellen Behrend, as she unveils the transformative potential of SGLT2 inhibitors for cats navigating the challenges of diabetes mellitus. She focuses on velagliflozin, a once-daily liquid oral SGLT2 inhibitor and brings her passion for endocrinology to the forefront, sharing her insights into this groundbreaking treatment originally successful in human type 2 diabetes. Join us as we dive into this new era of easier diabetes management for your feline friends. In our engaging discussion, we venture into the evolving landscape of diabetes care in pets, spotlighting novel treatments and their unexpected benefits for renal and cardiac health in cats. Ellen’s personal anecdotes underscore the value of critical thinking and mentorship within veterinary studies, while we demystify common misconceptions about SGLT2 inhibitors, particularly diabetic ketoacidosis risks. Don’t miss Ellen’s article in JAVMA and join us next week for more insightful conversations. Please remember to rate and review us on your favorite podcast platform!JAVMA open access article: https://doi.org/10.2460/javma.24.03.0174INTERESTED IN SUBMITTING YOUR MANUSCRIPT TO JAVMA ® OR AJVR ® ? JAVMA ® : https://avma.org/JAVMAAuthors AJVR ® : https://avma.org/AJVRAuthorsFOLLOW US:JAVMA ® : Facebook: Journal of the American Veterinary Medical Association - JAVMA | Facebook Instagram: JAVMA (@avma_javma) • Instagram photos and videos Twitter: JAVMA (@AVMAJAVMA) / Twitter AJVR ® : Facebook: American Journal of Veterinary Research - AJVR | Facebook Instagram: AJVR (@ajvroa) • Instagram photos and videos Twitter: AJVR (@AJVROA) / Twitter JAVMA ® and AJVR ® LinkedIn: https://linkedin.com/company/avma-journals

Ver todos los episodios